1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: major diversified
SANIGEN Co., Ltd.

SANIGEN Co., Ltd.

KKRX:188260
2,020.00
KRW
0.00
(0.00%)
-792.54EPS
26.56BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8,085.4
9,359.34
9,773.82
9,966.23
3,960.58
2,223.99
2,163.17
787.52
Basic EPS, GAAP
-1,254
-1,034
-1,659
-1,514
-1,814
-945
-820
-650.21
Free Cash Flow per Basic Share
-385.9
-574.73
-1,166.98
-2,493.37
-794.37
-832.27
-618.52
-313.3
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-618.16
-992.11
-1,371.79
-1,934.1
2,022.98
1,160.8
348.91
829.38
Tangible Book Value per Share
-626.3
-997.57
-1,375.13
-1,945.96
2,014.76
1,155.89
346.44
828.72
Basic Weighted Avg Shares
3
3
3
3
5
7
7
8
Sales/Revenue/Turnover
20,262
23,487
25,221
26,758
20,187
15,428
15,354
6,234
Operating Margin (%)
-4.19
-8.75
-11.36
-15.21
-32.08
-37.85
-28.49
-63.68
Depreciation Expense
412
531
603
812
959
955
937
932
Net Income, GAAP
-3,142
-2,595
-4,281
-4,065
-9,246
-6,555
-5,820
-5,147
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-15.51
-11.05
-16.97
-15.19
-45.8
-42.49
-37.91
-82.56
Working Capital
-4,239
-6,569
-9,003
-15,184
13,662
7,488
2,402
10,975
LT Debt
334
508
452
1,619
2,987
1,682
1,737
1,745
Total Equity
-4,158
-6,629
-9,166
-12,924
13,397
8,240
2,477
11,422
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
-60.6
-108.63
-51.82

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
857
1,548
2,582
LT Borrowings
1,707
1,617
1,526
LT Finance Leases
29
286
219
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
14
Market Capitalization
13,650
12,060
26,565

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,240
5,278
19,130
Cash, Cash Equivalents & STI
1,584
1,100
14,365
Accounts Receivable, Net
1,847
1,878
2,097
Inventories
1,808
1,715
1,981
Total Current Liabilities
3,838
4,074
8,155
Payables & Accruals
- -
- -
- -
ST Debt
857
1,548
2,582
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-46.57%
-69.94%
Free Cash Flow
- -
42.04%
-23.96%
Net Income, GAAP
- -
29.42%
-11.21%
Sales/Revenue/Turnover
- -
-7.03%
-0.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,731
5,681
6,586
-1,571
15,428
2025
4,214
4,049
4,050
-4,939
15,354
2026
3,310
3,813
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-236.4
-191
-159
-357.37
-945
2025
-228
-190
-131.98
-446.22
-820
2026
-126.46
-14
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Sector
Process industries
Industry
Chemicals: major diversified
Address
Anyang-si South Korea
IPO Date
Nov 3, 2023
Website
sanigen.kr
Similar Companies
Hektas Ticaret T.A.S. (BIST:HEKTS)
AARTI Industries Ltd (NSE:AARTIIND)
Aether Industries Ltd. (NSE:AETHER)
Mitsui & Co.,Ltd (TSE:8031)
Saudi Basic Industries Corp. (TADAWUL:2010)
Raghav Productivity Enhancers Ltd. (NSE:RPEL)
Business
SANIGEN Co., Ltd. is a South Korea-based biotechnology company primarily engaged in the development, manufacture, and commercialization of molecular diagnostic solutions, food safety testing systems, and microbial genomics services. Founded in 2005 and headquartered in Anyang, Gyeonggi-do, South Korea, the company operates across specialized biotechnology sectors encompassing food pathogen diagnostics, molecular biology reagents, next-generation sequencing analysis, and hygiene management solutions. SANIGEN provides an integrated portfolio of products and services, including real-time polymerase chain reaction and isothermal amplification diagnostic kits under the GeN-Check and GeneChecker product lines for the rapid detection of foodborne pathogens such as Salmonella, Listeria monocytogenes, Escherichia coli, Norovirus, and Campylobacter; microbial identification, metagenomics, and microbiome sequencing services utilizing its proprietary GeN-Seq bioinformatics platform; rapid point-of-care testing devices, automated extraction instruments, and diagnostic consumables; industrial hygiene and contamination control products, including SaniZone and SaniPure specialized disinfectants, surface sanitizers, and bio-decontamination solutions; and comprehensive food safety inspection, quality validation, Hazard Analysis and Critical Control Point consulting, and regulatory analytical testing services. The company serves food processors, agricultural enterprises, biotechnology research laboratories, clinical institutions, and government health authorities across South Korea and international export markets. In recent operational and strategic developments, SANIGEN transitioned its public listing to the KOSDAQ exchange through a merger with KB No.23 Special Purpose Acquisition Company to fund technological scaling and global expansion. Furthermore, the company has expanded its strategic distribution partnerships across Southeast Asia, Japan, and North America, broadened its portfolio of automated multiplex molecular diagnostic platforms, and advanced the integration of artificial intelligence-driven genomic databases for foodborne pathogen tracing and antimicrobial resistance surveillance.